RL
Relay Therapeutics, Inc.
RLAY · NASDAQ
$19.04 +0.87% (+$0.16)
1M -3.59%
Market Cap $4.17B
P/E Ratio -
Div. Yield -
ROE 42.27%
Piotroski F-Score Weak
3/9Valuation
21 /100
Expensive P/S 402.50x
P/B 4.68x
P/E N/A
Growth
78 /100
Growing Rev. growth 123.20%
Book val. growth 15.81%
EPS growth N/A
Profitability
0 /100
Weak Gross margin 566.59%
Net margin 2,763.64%
Op. margin 2,999.38%
Quality
0 /100
Poor ROIC 33.72%
ROE 42.27%
ROA 29.57%
Debt
100 /100
Low Debt/Equity 0.03x
Current ratio 18.27x
Int. coverage N/A
Stability
31 /100
Unstable Beta 1.70x
Rev. volatility 1,014.00%
EPS volatility 19.85%
Bulios Scoring opisuje kakovost in preteklost podjetja, ne prihodnjega donosa. Visok rezultat ni nakupni signal. Izvedite več
Vprašajte StockBota o RLAY
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Sanjiv K. Patel
Employees
202
Headquarters
Cambridge
Prihajajoči dogodki
05 NOV.
Earnings
Upcoming earnings report